ZEB1、LAMP5在结直肠癌组织中的表达水平分析及预后预测价值分析

来源期刊：广州医药 | 228-234 发布时间：2025-03-10 收稿时间：2025/11/13 18:55:06 阅读量：39

作者：: 彭旭,

焦璐,

韩莹,

杨静,

赵信喜,

关键词：: 转录因子E盒结合锌指蛋白1 溶酶体相关膜蛋白5 结直肠癌病理特征预后预测; transcription factor E-box binding to zinc finger protein 1 lysosome associated membrane protein 5 colorectal cancer pathological features prognostic prediction

DOI：: 10.20223/j.cnki.1000-8535.2025.02.013

收稿时间：: 2024-04-29
修订日期：
接收日期：
引用总数：: 0

目的探讨转录因子E盒结合锌指蛋白1（ZEB1）、溶酶体相关膜蛋白5（LAMP5）在结直肠癌组织中的表达水平分析及预后预测价值。方法选取驻马店市中心医院2018年1月—2020年1月收治的120例结直肠癌患者,分别采取所有患者的结直肠癌组织及癌旁组织进行免疫组化染色,对比ZEB1、LAMP5阳性率。对比不同病理特征结直肠癌患者ZEB1、LAMP5表达水平差异。对所有患者进行4年随访,依照随访结果将患者分为2个亚组,即预后不良组（n=35）和预后良好组（n=85）,对比两组患者一般临床特征及ZEB1、LAMP5表达水平,应用Logistic回归分析ZEB1、LAMP5对结直肠癌预后的预测价值。结果结直肠癌组织ZEB1、LAMP5相对表达量（38.26±5.49、26.77±3.85）与ZEB1、LAMP5阳性率（86.67%、72.22%）高于癌旁组织（15.46±2.54、8.04±1.59、23.33%、15.56%],对比差异有统计学意义（t=41.280,χ²=25.437;t=49.255,χ²=16.071;P<0.05）。不同TNM分期[Ⅰ~Ⅱ期（35.55±4.13）、Ⅲ~Ⅳ期（42.32±4.75）]、淋巴结转移患者[是（44.37±4.28）、否（35.84±3.77）]、肿瘤分化程度[低分化（35.27±4.57）、中高分化（41.34±4.60）]ZEB1相对表达量对比差异有统计学意义（t=-8.281,P<0.001;t=10.746,P<0.001;t=-7.253,P<0.001）;不同TNM分期[Ⅱ期（24.88±3.37）、Ⅲ~Ⅳ期（29.61±2.57）]、淋巴结转移[是（30.72±2.19）、否（25.21±3.19）]、肿瘤分化程度[低分化（24.57±3.62）、中高分化（29.04±2.55）]患者LAMP5相对表达量对比差异有统计学意义（t=-8.254,P<0.001;t=9.227,P<0.001;t=-7.797,<0.001）;预后良好组与预后不良组患者性别、年龄、大体类型、肿瘤大小对比差异无统计学意义（P>0.05）,预后良好组与预后不良组患者TNM分期、淋巴结转移、肿瘤分化程度、ZEB1、LAMP5阳性比例对比差异有统计学意义（P<0.05）;Logistic回归分析显示：淋巴结转移、ZEB1阳性、LAMP5阳性为结直肠癌预后不良独立预测因素（P<0.05）。结论 ZEB1、LAMP5在结直肠癌组织中呈现高表达状态,且与结直肠癌的发生有关,同时ZEB1、LAMP5是结直肠癌预后的独立预测因素,两者有希望成为结直肠癌的治疗靶点。

Objective To investigate the expression levels and prognostic value of transcription factor E-box binding to zinc finger protein 1（ZEB1）and lysosomal associated membrane protein 5（LAMP5）in colorectal cancer tissues. Methods A total of 120 colorectal cancer patients admitted to a hospital from January 2018 to January 2020 were selected．Immunohistochemical staining was performed on the colorectal cancer tissues and adjacent tissues of all patients,and the positivity rates of ZEB1 and LAMP5 were compared．The expression levels of ZEB1 and LAMP5 in colorectal cancer patients with different pathological characteristics were compared．All patients were followed up for 4 years and divided into two subgroups based on the follow-up results,namely the poor prognosis group（n=35）and the good prognosis group（n=85）．The general clinical characteristics and expression levels of ZEB1 and LAMP5 were compared between the two groups．Logistic regression analysis was used to evaluate the predictive value of ZEB1 and LAMP5 for the prognosis of colorectal cancer. Results The relative expression level of ZEB 1 and LAMP 5 in colorectal cancer tissues [（38.26±5.49）,（26.77±3.85）] and the positive rate of ZEB 1 and LAMP 5（86.67%,72.22%）were significantly higher than that of adjacent tissues [（15.46±2.54）,（8.04±1.59）,23.33%,15.56%],the contrast difference was statistically significant（t=41.280,χ²=25.437;t=49.255,χ²=16.071;P<0.05）．Relative ZEBI expression levels in different TNM stages [I-Ⅱstage（35.55±4.13）,Ⅲ-Ⅳstage（42.32±4.75）],lymph node metastasis[Yes（44.37±4.28）,No（35.84±3.77）],degree of tumor differentiation [hypodifferentiated（35.27±4.57）,and middle or high differentiated（29.04±2.55）],those differences were statistically significant（t=-8.254,P<0.001;t=9.227,P<0.001;t=-7.797,P<0.001）．The relative expression of LAMP 5 between different TNM stages [I-Ⅱstage（24.88±3.37）,Ⅲ-Ⅳstage（29.61±2.57）],lymph node metastasis [yes（30.72±2.19）,no（25.21±3.19）],degree of tumor differentiation [hypodifferentiated（24.57±3.62）,and middle or high differentiated（29.04±2.55）],the contrast was statistically significant（t=-8.254,P<0.001;t=9.227,P<0.001;t=-7.797,P<0.001）．There were no differences in gender,age,gross type,and tumor size between the good prognosis group and the poor prognosis group（P>0.05）,while there were differences in TNM stages,lymph node metastasis,tumor differentiation degrees,ratio of ZEB 1 and LAMP 5（P<0.05）．Logistic regression analysis showed that TNM stage,lymph node metastasis,ZEB 1 positive,and LAMP 5 positive were independent predictive factors of poor prognosis in colorectal cancer（P<0.05）. Conclusions ZEB1 and LAMP5 are highly expressed in colorectal cancer tissues and closely related to the occurrence and development of colorectal cancer．ZEB1 and LAMP5 are independent prognostic factors for colorectal cancer,and they have the potential to become therapeutic targets for colorectal cancer．

1、张倩,段婷婷,任玉宝.结直肠癌组织中PLOD2、ZEB1表达变化及意义[J].山东医药,2022,62(10):67-70.

2、阿孜古丽·阿布都热合曼,李宇翔,赵寰宇,等.三阴性乳腺癌中溶酶体相关膜蛋白-2表达水平的临床意义及预后价值[J].转化医学杂志,2022,11(6):351-354.

3、张翔,周宏,周云海.胃癌中LAMP5表达及预后意义分析[J].交通医学,2023,37(1):33-38.

4、金亚,张教国.LncRNA XIST调控miR-200b/ZEB1轴参与儿童急性髓系白血病阿柔比星耐药的机制研究[J].中国免疫学杂志,2022,38(20):2450-2454.

5、袁祎,丁森君,李丽洁,等.卵巢癌组织锌指E盒同源结合蛋白1、微小RNA-574-3p的表达及其临床意义研究[J].中国性科学,2022,31(7):63-67.

6、张芳芳,张可刚,赵新凤,等.缺氧缺血性脑损伤新生大鼠大脑皮层中LAMP-2A和HSC70的表达变化及意义[J].中国妇幼保健,2023,38(9):1696-1699.

7、杨书瀚,裴筱涵,祁义军.LAMP5在结直肠癌发生发展和预后中的作用[J].安徽医科大学学报,2022,57(8):1338-1344.

8、赵维波,孔令甲,敬长春.白花丹素调控锌指E盒结合ZEB1的表达对结直肠癌细胞增殖、凋亡的影响[J].河北医药,2022,44(22):3380-3383.

9、 LI H,BOAKYE D,CHEN X,et al.Association of body mass index with risk of early-onset colorectal cancer:Systematic review and Meta-Analysis[J].Am J Gastroenterol,2021,116(11):2173-2183.

10、 LI X,LI J,HU Q,et al.Association of physical weight statuses defined by body mass index(BMI)with molecular subtypes of premenopausal breast cancer:A systematic review and meta-analysis[J].Breast Cancer Res Treat,2024,203(3):429-447.

11、 TZENIOS N,TAZANIOS M E,CHAHINE M.The impact of body mass index on prostate cancer:An updated systematic review and meta-analysis[J].Medicine(Baltimore),2022,101(45):e30191.

12、张旭东,单李天一,王蓉,等.沉默调节蛋白3通过mTOR信号途径调节溶酶体功能抑制U87细胞凋亡[J].陆军军医大学学报,2023,45(18):1916-1926.

13、陈昊,方攀奇,刘桐言,等.肿瘤相关性成纤维细胞高表达LncRNA ZEB1-AS1促进肺腺癌血管生成的功能机制[J].医学研究生学报,2022,35(7):680-686.

14、黄金梅,唐婷,韦柳叶,等.MEBT/MEBO对糖尿病大鼠难愈合创面中ZEB1/LAMA3/ITGA3信号通路表达的影响[J].现代中西医结合杂志,2023,32(10):1322-1329.

15、钟淙,石琴,章超.lncRNA MALAT1调控miR-144-3p/ZEB1对肺癌放射敏感性的影响[J].实用肿瘤杂志,2022,37(4):307-314.

16、 REZAEI S,DE OLIVEIRA L C,GHANAVATI M,et al.The effect of anamorelin(ONO-7643)on cachexia in cancer patients:Systematic review and meta-analysis of randomized controlled trials[J].J Oncol Pharm Pract,2023,29(7):1725-1735.

17、 IRRAZABAL T,THAKUR B K,CROITORU K,et al.Preventing colitis-associated colon cancer with antioxidants:A systematic review[J].Cell Mol Gastroenterol Hepatol,2021,11(4):1177-1197.

18、 CUK P,KJ?R M D,MOGENSEN C B,et al.Short-term outcomes in robot-assisted compared to laparoscopic colon cancer resections:A systematic review and meta-analysis[J].Surg Endosc,2022,36(1):32-46.

19、 LARSSON S C,BURGESS S.Causal role of high body mass index in multiple chronic diseases:A systematic review and meta-analysis of Mendelian randomization studies[J].BMC Med,2021,19(1):320.

20、中国医师协会结直肠肿瘤专业委员会外科专委会.中国结直肠癌县域医师诊疗指南-外科部分(2019版草案)[J].中华结直肠疾病电子杂志,2019,8(5):433-438.

21、朱旭超,窦长松,张钰,等.黑质LAMP2A过表达改善帕金森病恒河猴模型的运动功能[J].中国比较医学杂志,2022,32(4):7-13.

22、聂伟,马迎萍.SLUG、ZEB1在宫颈癌组织中的表达及与预后的关系[J].现代肿瘤医学,2022,30(8):1454-1458.

23、张悦健,何甜甜,林陶秀,等.琥珀散对人MenSCs植入式子宫内膜异位症裸鼠异位病灶及Beclin1、ZEB1表达的影响[J].药物评价研究,2023,46(2):294-304.

24、郭益辰,李卫平,杨瑞婷,等.ZEB1、AR、E-Cadherin和N-Cadherin在前列腺癌组织中的表达及意义[J].现代泌尿外科杂志,2023,28(7):627-631.

25、 LIU H,GU H,KUTBI EH,et al.Association of IGF-1 and IGFBP-3 levels with gastric cancer:A systematic review and meta-analysis[J].Int J Clin Pract,2021,75(11):e14764.